Tiemann C, Prohaska W, Körfer R, Körner M, Brinkmann T, Kleesiek K
Institut für Laboratoriums- und Transfusionsmedizin, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
Eur J Clin Chem Clin Biochem. 1997 Sep;35(9):661-7. doi: 10.1515/cclm.1997.35.9.661.
We investigated the influence of cyclosporine A on the concentration of tissue factor pathway inhibitor and von Willebrand factor antigen in plasma of heart transplant outpatients. Tissue factor pathway inhibitor was quantified in plasma of blood donors (n = 50) and heart transplant outpatients (n = 50) by a chromogenic substrate assay with a mean of 32.4 micrograms/l and 98.2 micrograms/l, respectively. Von Willebrand factor antigen was determined with an enzyme-linked immunoassay with a mean of 90.9% for blood donors and 184.5% in plasma of heart transplant recipients. In addition, we investigated the effect of cyclosporine A on endothelial cell cultures over an incubation period of four days. A dose-dependent effect of cyclosporine A on the release of endothelial tissue factor pathway inhibitor and von Willebrand factor antigen was determined in a concentration range from 100 to 200 micrograms/l cyclosporine A. The tissue factor pathway inhibitor and von Willebrand factor antigen concentrations in the cell culture supernatant increased during the incubation time according to the cyclosporine A concentration 2-3 fold and 2 fold, respectively. For a further elucidation of the cyclosporine A effect we investigated the influence of cremophor EL, the vehicle of cyclosporine A. Cremophor EL alone did not increase the tissue factor pathway inhibitor release. However, the release was enhanced 2-4 fold after co-stimulation with the calcium ionophore A 23187 (10(-4) mol/l) in a concentration-dependent mode. We conclude that a generalized endothelial damage or activation is most probably caused by cyclosporine A and its vehicle cremophor EL. This process probably depends upon the increase of cytosolic free calcium, as described for the liberation of von Willebrand factor by endothelial cells.
我们研究了环孢素A对心脏移植门诊患者血浆中组织因子途径抑制物和血管性血友病因子抗原浓度的影响。通过发色底物法对50名献血者和50名心脏移植门诊患者的血浆中的组织因子途径抑制物进行定量,其平均值分别为32.4微克/升和98.2微克/升。采用酶联免疫法测定血管性血友病因子抗原,献血者血浆中的平均值为90.9%,心脏移植受者血浆中的平均值为184.5%。此外,我们研究了环孢素A在四天的孵育期内对内皮细胞培养物的影响。在环孢素A浓度为100至200微克/升的范围内,确定了环孢素A对内皮组织因子途径抑制物和血管性血友病因子抗原释放的剂量依赖性效应。细胞培养上清液中的组织因子途径抑制物和血管性血友病因子抗原浓度在孵育期间根据环孢素A浓度分别增加了2至3倍和2倍。为了进一步阐明环孢素A的作用,我们研究了环孢素A的载体聚氧乙烯蓖麻油EL的影响。单独使用聚氧乙烯蓖麻油EL不会增加组织因子途径抑制物的释放。然而,在与钙离子载体A 23187(10^(-4)摩尔/升)共同刺激后,释放以浓度依赖模式增强了2至4倍。我们得出结论,环孢素A及其载体聚氧乙烯蓖麻油EL很可能导致了普遍的内皮损伤或激活。这一过程可能取决于细胞内游离钙的增加,正如内皮细胞释放血管性血友病因子的情况一样。